Regulatory Updates, Clinical Trial Results, and Stock Price Movements - Research Report on Johnson & Johnson, Cubist, Regeneron,

   Regulatory Updates, Clinical Trial Results, and Stock Price Movements -
 Research Report on Johnson & Johnson, Cubist, Regeneron, Medtronic, and Jazz
                               Pharmaceuticals

PR Newswire

NEW YORK, December 19, 2013

NEW YORK, December 19, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting John &
Johnson (NYSE: JNJ), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Regeneron
Pharmaceuticals Inc. (NASDAQ: REGN), Medtronic, Inc. (NYSE: MDT), and Jazz
Pharmaceuticals plc (NASDAQ: JAZZ). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Johnson & Johnson Research Report

On December 12, 2013, Janssen Research & Development, LLC (Janssen Research),
part of the Janssen Pharmaceutical Companies of Johnson & Johnson (Johnson &
Johnson), announced that it has received a complete response letter from the
US Food and Drug Administration (FDA) regarding its New Drug Application (NDA)
for a fixed-dose combination (FDC) of canagliflozin and immediate-release
metformin to treat adults with type 2 diabetes. According to the Company, the
complete response letter requested additional information to support the
comparability of the twice-daily dosing regimen of canagliflozin (as part of
the canagliflozin and metformin FDC) and the once-daily dosing of
canagliflozin as a single agent. Norman Rosenthal, MD, FACE, FACP,
canagliflozin compound development leader at Janssen Research, said, "We
continue to have productive discussions with the FDA and will work closely
with the agency to advance this application. We look forward to addressing
questions from the FDA as soon as possible and remain committed to providing
therapeutic options that meet the needs of the type 2 diabetes community."
Janssen Research further reported that it believes it can supply this
information based on available clinical data from the comprehensive Phase 3
clinical development program for canagliflozin. The Full Research Report on
John & Johnson - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/07a8_JNJ

--

Cubist Pharmaceuticals Inc. Research Report

On December 16, 2013, Cubist Pharmaceuticals Inc. (Cubist) announced positive
top-line results from the Company's pivotal Phase 3 clinical trial of its
antibiotic candidate ceftolozane/tazobactam in complicated intra-abdominal
infections (cIAI). According to the Company, ceftolozane/tazobactam, in
combination with metronidazole, met the US Food and Drug Administration (FDA)
and the European Medicines Agency (EMA) defined primary endpoints of
statistical non-inferiority compared to meropenem. Cubist reported that the
primary endpoint was a clinical cure rate of 26 - 30 days after the initiation
of therapy. According to Cubist, for the FDA, the primary analysis was
conducted in the Microbiological Intent-to-Treat (MITT) population, where the
non-inferiority margin was 10% and the lower and upper bounds of the 95%
confidence interval were -8.9% and 0.5%, respectively. Cubist further reported
that for the EMA, the primary analysis population was Clinically Evaluable
(CE) patients, where the non-inferiority margin was 12.5% and the lower and
upper bounds of the 99% confidence interval were -4.2% and 4.3%, respectively.
The Full Research Report on Cubist Pharmaceuticals Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/92f2_CBST

--

Regeneron Pharmaceuticals Inc. Research Report

On December 16, 2013, Regeneron Pharmaceuticals Inc.'s (Regeneron) stock
declined 0.42%, ending the day at $268.45. Over the previous three trading
sessions, shares of Regeneron declined 0.58% compared to the Nasdaq Composite
which gained 0.64% during the same period. The Full Research Report on
Regeneron Pharmaceuticals Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/8ea7_REGN

--

Medtronic, Inc. Research Report

On December 9, 2013, Medtronic, Inc. (Medtronic) announced the first-in-human
implant of Micra Transcatheter Pacing System (TPS). The Company reported that
the device, which is an investigational device worldwide, was implanted in a
patient in Linz, Austria as part of the Medtronic global pivotal clinical
trial. Reporting the device as the world's smallest pacemaker, Medtronic
informed that at one-tenth the size of a conventional pacemaker, and
comparable in size to a large vitamin, the Micra TPS is delivered directly
into the heart through a catheter inserted in the femoral vein. Medtronic
added that after it is positioned, the pacemaker is securely attached to the
heart wall and can be repositioned if needed. Clemens Steinwender, M.D., Head
of Cardiology at the Linz General Hospital in Linz, Austria, said, "Because of
its small size and unique design, the Micra TPS can be introduced directly
into the heart via a minimally invasive procedure, without the need for leads.
The combination of this novel technology with a transcatheter procedure can
benefit patients by potentially reducing pocket or lead complications and
recovery times observed with traditional surgical pacemaker implants." The
Full Research Report on Medtronic, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/bc94_MDT

--

Jazz Pharmaceuticals plc Research Report

On December 16, 2013, Jazz Pharmaceuticals plc's (Jazz Pharmaceuticals) stock
declined 2.04%, ending the day at $112.19. Over the previous three trading
sessions, shares of Jazz Pharmaceuticals declined 2.63% compared to the Nasdaq
Composite which gained 0.64% during the same period. The Full Research Report
on Jazz Pharmaceuticals plc - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/5fe3_JAZZ

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.